Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514579 · ClinicalTrials.gov registry record · Phase 2
Adult Double Cord Blood Transplant Study
A Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT00514579 is a Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 56 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00514579, a Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation, has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The hypothesis of the study is double unit umbilical cord blood transplantation in adults will be associated with a one year survival rate of at least 40%.
Conditions Studied
Interventions
- PROCEDURE Cord blood transplantation
Study Locations (10)
California
- City of Hope - Duarte
- University of California at Los Angeles - Los Angeles
Ohio
- Case Western Reserve University - Cleveland
- Ohio State University Medical Center - Columbus
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Blood and Marrow Transplant Program at Northside Hospital - Atlanta
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Oklahoma
- University of Oklahoma - Oklahoma City
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514579
The ClinicalTrials.gov registry entry for NCT00514579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Cord blood transplantation is the first listed.
NCT00514579 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Ohio, Florida.
Frequently Asked Questions
What is clinical trial NCT00514579 about?
NCT00514579 is a clinical study titled "Adult Double Cord Blood Transplant Study". The hypothesis of the study is double unit umbilical cord blood transplantation in adults will be associated with a one year survival rate of at least 40%.
What is the current status of trial NCT00514579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2007-08. Estimated completion is 2013-08.
What conditions does trial NCT00514579 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Cord Blood Stem Cell Transplantation.
What interventions are being tested in trial NCT00514579?
The interventions under investigation include: Cord blood transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00514579?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00514579 being conducted?
This trial has 10 study locations across California, Florida, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RECRUITING · Phase 2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
RECRUITING · Phase 2
Explore more on PlainTrial
Hematologic Malignancies
All registered trials for this condition
Cord Blood Stem Cell Transplantation
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.